Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L31 pseudogene 6 (RPL31P6) is a processed pseudogene in the human genome. It does not encode a functional protein. The canonical gene, RPL31, encodes a structural protein of the 60S ribosomal subunit involved in protein synthesis[3][4][7]. RPL31P6, however, is a non-protein-coding sequence derived from duplication or retrotransposition of the functional RPL31 gene, and there is no evidence that it plays any direct biological or pathological role. It is not considered a therapeutic target, receptor, enzyme, or participant in known drug interactions[6]. Notes: - RPL31P6 is a pseudogene: it is not a protein, receptor, enzyme, or an established therapeutic target. - There is no concrete evidence it functions as a biomarker or is involved in disease. - RPL31, the parent gene, is a ribosomal protein with known roles in protein synthesis and association with diseases like Diamond-Blackfan anemia[7], but RPL31P6 itself does not share these roles. - The entry is "incorrect" for most therapeutic target curation, as pseudogenes are generally not considered druggable or functional targets[6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L31 pseudogene 6 (RPL31P6).